2015
DOI: 10.1016/j.foodpol.2015.06.002
|View full text |Cite
|
Sign up to set email alerts
|

International legislation on nutrition and health claims

Abstract: a b s t r a c tThe increasing public interest in dietary health benefits led to the development of different legislative texts on nutrition and health claims worldwide. Following a review of legislation of 28 jurisdictions, three prominent differences were discerned, concerning (i) the labelling of different types of nutrition and health claims and their permission; (ii) variations arising in the (pre-marketing) authorisation procedures; and (iii) the use of the scientific minority opinion in substantiating cl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
23
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
4
4

Relationship

1
7

Authors

Journals

citations
Cited by 45 publications
(23 citation statements)
references
References 31 publications
0
23
0
Order By: Relevance
“…Cotterill and Dhar (2003) employ a similar approach on the Boston fluid milk market. Following Nimon and Beghin (1999), Steiner (2004), Boer and Bast (2015), in our model we assume that label is a valuable source of information for consumers and consumers use this information in their purchase decisions. We use this framework to explain the choice variation among households based on their demographic profiles.…”
mentioning
confidence: 99%
“…Cotterill and Dhar (2003) employ a similar approach on the Boston fluid milk market. Following Nimon and Beghin (1999), Steiner (2004), Boer and Bast (2015), in our model we assume that label is a valuable source of information for consumers and consumers use this information in their purchase decisions. We use this framework to explain the choice variation among households based on their demographic profiles.…”
mentioning
confidence: 99%
“…Although this study focuses on substantiating the efficacy of HDSs and HMPs, previous research showed that other aspects of health claim authorization procedures also differ across international jurisdictions (de Boer & Bast, ). Similar to the EU, the legal framework of the United States, for example, does not provide the possibility to substantiate efficacy of HDSs with evidence on traditional use (Table ).…”
Section: Discussionmentioning
confidence: 99%
“…Depending on how a product is classified, different requirements are set within these jurisdictions regarding the evidence to substantiate safety and efficacy. In the United States, for example, manufacturers should merely notify the FDA when marketing a HDS, whereas a new drug application including the evaluation of the evidence is required before the marketing of a HMP (de Boer & Bast, ; Verma, ). Because it is increasingly recognized that botanicals, including those in HDSs, may pose risks to consumers, the regulation of these product has also been highly debated in the scientific community (Marcus & Grollman, ; Mukherjee et al., ).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Over the past decades, many countries around the world have undertaken actions to regulate the use of health claims and symbols on food products: Japan [3,4], China [5], Australia & New Zealand [6], the USA [7] or Canada [8], to name a few. For a recent overview, see [9].…”
Section: Introductionmentioning
confidence: 99%